HI
TCRT icon

HBK Investments’s Alaunos Therapeutics TCRT Stock Holding History

HBK Investments’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-421
Closed -$469K – 1083
2016
Q1 		$469K Sell
421
-270
-39% -$276K ﹤0.01% 744
2015
Q4 		$861K Buy
+691
New +$1.14M 0.01% 611

Other funds holding TCRT

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BGA
Belmont Global Advisors Dallas, Texas $106M AUM 2.89% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

HBK Investments's TCRT Position: Q2 2016 in Review

HBK Investments sold out of Alaunos Therapeutics (TCRT) in Q2 2016, closing a stake of 421 shares — an estimated $469K sold.

HBK Investments first reported a position in TCRT in Q4 2015 and held it in 2 quarters. The position peaked at $861K in Q4 2015. 154 funds tracked by Wall St. Rank hold TCRT as of Q2 2016.

  • HBK Investments reported no remaining Alaunos Therapeutics position as of Q2 2016 after selling out during the quarter.
  • HBK Investments sold 421 Alaunos Therapeutics shares in Q2 2016, an estimated $469K.
  • HBK Investments first reported a position in Alaunos Therapeutics in Q4 2015 and held it in 2 quarters.
  • HBK Investments's Alaunos Therapeutics position peaked at $861K in Q4 2015.
  • 154 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2016.

Based on HBK Investments's 13F filing for Q2 2016, filed 15 Aug 2016.